HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On ‘Unclear Path’
The merger agreement between EW Partners and TherapeuticsMD Inc (NASDAQ:TXMD) was terminated, with EW Partners not acquiring the majority of shares…
HC Wainwright Reiterates On Pluristem After Encouraging Initial Data
Yesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3 trial evaluating PLX-PAD in 240 patients for muscle recovery following hip fracture surgery.
Athenex Receives Notice Of Allowance For U.S. Patent Titled ‘METHODS OF TREATING AND/OR PREVENTING ACTINIC KERATOSI’
https://patentcenter.uspto.gov/#!/applications/16804092/ifw/docs
Novavax (NVAX) Down As EU Adds Side Effects To COVID Jab Label
Shares of Novavax (NASDAQ: NVAX) fell 26.2% on Jul 14, after the European Medicines Agency's (TSE: EMA) Pharmacovigilance Risk Assessment Committee ("PRAC") updated the product label of Nuvaxovid, the company's COVID-19 vaccine, to include some potential side effects like severe aller
Alnylam Hits Moderna With Another Patent Infringement Suit-Related To COVID-19 Vaccine
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) added one more patent infringement lawsuit against Moderna Inc (NASDAQ:MRNA), claiming it violated a newly obtained patent. The…
Adverum Biotechnologies Presents Best-Corrected Visual Acuity And Central Subfield Thickness Analyses After Single IVT Injection Of ADVM-022 (Ixo-vec) In OPTIC Study In Wet AMD
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
- Study participants had
Why Codexis Shares Are Slumping Today
Codexis Inc (NASDAQ:CDXS) expects Q2 sales of approximately $38 million and FY22 sales of 135 million to $141 million, below the…
NexImmune Shares Soar Following FDA’s Clearance To Initial-Stage HPV Cancer Study
NexImmune, Inc. (NASDAQ: NEXI) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its first cellular therapy product candidate NEXI-003 addressing solid tumors.